Breast Cancer

Women's Health

 

Breast Cancer Treatment - What is available?

Home
Blog - What's New?
Abortion
Acne
Amenorrhoea - Absent Periods
Anatomy Female
Birth Control
Bladder Symptoms
Breast Feeding
Cancer in Women
Childbirth
Diet / Weight Loss
Dysmenorrhoea
Ectopic Pregnancy
Endometrial Ablation
Endometriosis
Female Sexual Problems
Female Sterilization
Fibroids
Urinary Tract Infection - UTI
HRT/HormoneReplacementTherapy
Hysterectomy
Infection
Infertility
Irritable Bowel Syndrome IBS
Libido - Sex Drive
Medication - Drugs
Menopause
Menorrhagia Heavy Periods
Menstruation Menstrual Cycle
Miscarriage
Obesity
Ovarian Cysts
Painful Sex - Dyspareunia
Pap Smear Test
PCOS
Pelvic Inflammatory Disease
Pelvic Pain
PMS- Premenstrual Syndrome
Pregnancy & Childbirth
Prolapse
SHOP / SHOPPING MALL UK
SHOP / Shopping Mall - USA
Ultrasound
Urinary Tract Infection - UTI
Urinary Incontinence
Vaginal Discharge
Viagra, Libido and Sex Drive.
Weight Loss-Dieting
Illustrations
The Author
Contact Us

Lancet. 2007 May 19;369(9574):1711-23.

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R.

Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. jack.cuzick@cancer.org.uk

Background:

Several trials have been done to assess treatment of premenopausal breast cancer with luteinising-hormone-releasing hormone (LHRH) agonists, but results have been inconclusive, especially for patients with hormone-receptor-positive cancer.

Methods:

We collected individual patients' data from published trials and did analyses focused on women with tumours positive for oestrogen receptor, progesterone receptor, or both. The main endpoints were recurrence and death after recurrence. FINDINGS: We obtained data for 11 906 premenopausal women with early breast cancer randomised in 16 trials. When used as the only systemic adjuvant treatment, LHRH agonists did not significantly reduce recurrence (28.4% relative reduction, 95% CI consistent with 50.5% reduction to 3.5% increase, p=0.08) or death after recurrence (17.8%, 52.8% reduction to 42.9% increase, p=0.49) in hormone-receptor-positive cancers. Addition of LHRH agonists to tamoxifen, chemotherapy, or both reduced recurrence by 12.7% (2.4-21.9, p=0.02); and death after recurrence by 15.1% (1.8-26.7, p=0.03). LHRH agonists showed similar efficacy to chemotherapy (recurrence 3.9% increase, 7.7% reduction to 17.0% increase; death after recurrence 6.7% reduction, 20.7% reduction to 9.6% increase; both not significant). No trials had assessed an LHRH agonist versus chemotherapy with tamoxifen in both arms. LHRH agonists were ineffective in hormone-receptor-negative tumours. INTERPRETATION: LHRH agonists provide an additional class of agents for treatment of premenopausal women with hormone-receptor-positive breast cancer. Optimum duration of use is unknown.



Back Home Up Next

Please click on the required question.